Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone Palmitate 3-Month Relapse Prevention in Schizophrenia
NCT01529515Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2012
- Primary completion
- Apr 2014
- Modality
- Metabolically Activated Prodrugs
- Countries
- 8
01
Overview
A Phase 3 trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Started May 2012; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01529515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01529515.